Regeneron Q2 Earnings Soar 53 Percent
🕓 Estimated Reading Time: 5 minutes Regeneron Pharmaceuticals (REGN) reported a robust 53% surge in Q2 earnings per share (EPS). The significant growth was driven by strong sales across its key therapeutic areas, notably Eylea and Dupixent. Analysts are closely monitoring the company's pipeline and future drug approvals following these results. The performance highlights a resilient period for the biopharmaceutical sector. Investors are evaluating the long-term implications for REGN stock analysis . Overview Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a remarkable financial performance for the second quarter of 2025, with earnings per share (EPS) rocketing an impressive 53% year-over-year. The biopharmaceutical giant reported adjusted earnings of $12.45 per share, significantly surpassing analyst expectations and signaling a period of robust growth. This substantial increase in Regeneron EPS underscores the company's strong operational efficiency and the su...